Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1718-1720

  Oliva, Alessandra ^a   D'Abramo, Alessandra ^a   D'Agostino, Claudia ^a   Iannetta, Marco ^a   Mascellino, Maria T ^a   Gallinelli, Carmela ^a   Mastroianni, Claudio M ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bacteraemia; Ertapenem; KPC; Meropenem; Nosocomial infections

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; COLISTIN; DAPTOMYCIN; ERTAPENEM; FOSFOMYCIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; CARBAPENEM DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; CASE REPORT; CREATININE CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENDOPROSTHESIS; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LEG REVASCULARIZATION; LETTER; PROSTHESIS INFECTION; TREATMENT RESPONSE; BACTEREMIA; DRUG COMBINATION; DRUG EFFECTS; FATALITY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ADULT; BACTEREMIA; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84903901479     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku027     Document Type: Letter

References (10)

1. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
2. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
3. Capone A, Giannella M, Fortini D et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: E23-30.
4. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55: 3002-4.
5. Giamarellou H, Galani L, Baziaka F et al. Effectiveness of a doublecarbapenem regimen for infections in humans due to carbapenemaseproducing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 2388-90.
6. Giske CG, Gezelius L, Samuelsen Ø et al. A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect 2011; 17: 552-6.
7. Ceccarelli G, Falcone M, Giordano A et al. Successful ertapenemdoripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 2900-1.
8. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-41.
9. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
10. Thomson KS. Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56: 4037.